Nanoform and Nacuity Pharmaceuticals sign Technology POC Agreement for two ophthalmic drug candidates

The agreement presents a unique opportunity to explore how nanoformed particles may enhance the performance of Nacuity’s proprietary ophthalmic drug product candidate formulations, inserts and implants

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Nacuity Pharmaceuticals, a Texas-based clinical stage pharmaceutical company, announce that they have signed a Technology Proof of Concept (“PoC”) Agreement, with compensation on standard commercial terms.

This will apply Nanoform’s award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates.

This work will explore the feasibility of the patented CESS process (“Controlled Expansion of Supercritical Solutions“) to produce nanoparticles of both molecules in an effort to enhance ophthalmic drug delivery.

Nacuity focuses on ophthalmology and leverages their diverse library of novel antioxidant molecules to address ocular diseases involving oxidative stress. Such stress has been implicated in a variety of ophthalmological conditions and diseases, such as retinitis pigmentosa (including Usher syndrome) cataract, cystinosis, age-related macular degeneration, corneal endothelial cell loss, diabetic retinopathy, glaucoma and presbyopia.

Many pharma and biotech companies struggle to realise the full therapeutic potential of their drug candidates stymied by physico-chemical limitations, solubility and bioavailability challenges. Active pharmaceutical ingredients converted to nanometer-sized particles using the CESS process may exhibit greater dissolution rate and intrinsic solubility and offer the potential to enhance penetration into tissues.

This presents a unique opportunity to explore how nanoformed particles may enhance the performance of Nacuity’s proprietary ophthalmic drug product candidate formulations, inserts and implants.

“Optimisation of particle size distribution in the nanometer range offers elegant potential for minimal ocular irritation and maximum bioavailability as well as efficacy,” said G Michael Wall, SVP and CSO, Nacuity Pharmaceuticals, Inc.

“We see significant interest in the ophthalmology field for Nanoform’s technologies. The team at Nacuity has a long and accomplished track record in this field and we are therefore delighted to announce this new relationship with them” said Prof Edward Hæggström, CEO of Nanoform.

“Exploring Nanoform’s novel nanoparticle technology opens up new possibilities for enhancing formulation performance of both NPI-001 and NPI-002 in the ophthalmology space. We are eager to work with Nanoform and hope that this joint effort yields innovations for patients struggling with everyday challenges of ocular diseases” said Halden Conner, Chairman, CEO, and Co-Founder of Nacuity Pharmaceuticals, Inc.

Featured Companies

Nanoform (more information, website)